AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update

AnaptysBio, Inc. (NASDAQ:ANAB) saw a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 6,030,000 shares, a drop of 8.6% from the January 15th total of 6,600,000 shares. Based on an average daily trading volume, of 662,000 shares, the days-to-cover ratio is presently 9.1 days. Approximately 23.3% of the shares of the company are sold short.

AnaptysBio Trading Up 10.0 %

Shares of AnaptysBio stock opened at $21.22 on Monday. The firm has a market capitalization of $645.72 million and a PE ratio of -3.49. The firm’s 50 day moving average is $15.75 and its 200 day moving average is $25.63. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $41.31.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Guggenheim lowered their price target on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. JPMorgan Chase & Co. lowered their price target on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. UBS Group raised their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. HC Wainwright reaffirmed a “neutral” rating and set a $19.00 price target on shares of AnaptysBio in a research report on Tuesday, February 4th. Finally, Truist Financial decreased their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.45.

Insider Transactions at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 6,646 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were acquired at an average cost of $12.95 per share, with a total value of $86,065.70. Following the completion of the transaction, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 33.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in AnaptysBio during the 4th quarter worth approximately $40,000. Values First Advisors Inc. acquired a new stake in AnaptysBio during the 3rd quarter worth approximately $49,000. nVerses Capital LLC boosted its position in AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,400 shares during the period. Finally, AlphaQuest LLC boosted its position in AnaptysBio by 1,891.5% during the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after buying an additional 4,237 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.